ELAB PMGC Holdings Inc.
$2.57▼ -0.39%
Healthcare
Other
Volume 7.3K
Avg Volume (10D) 8.4K
Key Metrics & Fundamentals
Market Cap
$2.08M
P/E Ratio
–
Div Yield
0.00%
52W Range
2.52 - 1491.84
% vs 50 MA
-38.49%
% vs 200 MA
-93.20%
RSI-14
23.1
MACD Histogram
+0.0700
Beta (1Y vs SPY)
3.82
Free Cash Flow
-$1.96M
Gross Rev
$1.31M
Gross Profit
$385,691
EBITDA
-$3.48M
COGS
$920,919
Operating Exp
$4.20M
Operating Income
-$3.82M
EBIT
-$3.82M
Pretax Income
-$2.96M
Net Income
-$2.94M
EPS (Diluted)
-0.60
Price & Volume History
Loading chart…
Recent News
PMGC Holdings Inc. Announces DBA as NorthStrive Holdings, Inc., Trademark License Agreement, and Website Update
GlobeNewswire · Oct 8, 2026 10:01 AM ET
PMGC Holdings (Nasdaq: ELAB) Announces Completion of $100 Million SPAC IPO, Launching NorthStrive Acquisition Corp. I (Nasdaq: NSAI) as First in Planned SPAC Sponsorship Franchise to Expand M&A Strategy
GlobeNewswire · Oct 1, 2026 8:00 AM ET
PMGC Unit Working With Charles River Laboratories for Muscle Health Probiotic Testing
MT Newswires · Sep 29, 2026 8:34 AM ET
NorthStrive Biosciences Partners with Charles River Laboratories to Advance Its EL-22 and EL-32 Engineered Probiotic Programs
GlobeNewswire · Sep 29, 2026 7:33 AM ET
PMGC Holdings Inc. (Nasdaq: ELAB) Secures Five-Year Royalty Stream from Elevai Skincare Sale Under Executed Payment Agreement with Longevity Health Holdings
GlobeNewswire · Sep 18, 2026 8:00 AM ET
NorthStrive Biosciences Expands AI-Driven Drug Discovery Program with Yuva Biosciences, Advancing Four Novel AI-Discovered Compounds Toward Lead Nomination for Potential Cardiac Disease and Obesity Therapeutic Applications
GlobeNewswire · Sep 1, 2026 7:45 AM ET
PMGC Holdings Terminates Previously Announced Acquisition LOI Following Due Diligence Review; Reaffirms Disciplined M&A Strategy and Expands Investment Across Aerospace & Defense Manufacturing Portfolio
GlobeNewswire · Aug 26, 2026 8:17 AM ET
PMGC Holdings Signs Orbit2Orbit Term Sheet for Microgravity Muscle Research
InvestorsHub · Aug 25, 2026 9:46 AM ET
PMGC Holdings Announces Term Sheet with Orbit2Orbit for NorthStrive Biosciences to Launch a Spaceflight Study of Its Myostatin and Activin A Assets, EL-22 and EL-32, Targeting Microgravity-Induced Muscle Loss
GlobeNewswire · Aug 25, 2026 7:30 AM ET
NorthStrive Biosciences Announces The Filing of Two U.S. Patent Applications Targeting Microgravity-Induced Muscle Loss During Long-Duration Spaceflight
GlobeNewswire · Aug 21, 2026 9:30 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See ELAB's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.